Successful Use of Remimazolam in a Dialysis Patient With End-Stage Renal Disease and a History of Cardiac Arrest Following Induction of Propofol Anesthesia: A Case Report

瑞米唑仑成功用于一名终末期肾病透析患者,该患者曾因丙泊酚麻醉诱导后发生心脏骤停:病例报告

阅读:1

Abstract

BACKGROUND: Remimazolam, an ultra-short-acting benzodiazepine, has minimal hemodynamic impact compared with propofol, making it a potentially safer alternative for patients at high cardiovascular risk. This report highlights the anesthetic management of a hemodialysis patient with end-stage renal disease who had a prior cardiac arrest induced by propofol-remifentanil anesthesia and subsequently underwent lumbar laminectomy with remimazolam. CASE PRESENTATION: A 69-year-old male with paroxysmal atrial fibrillation, diabetes mellitus, and dialysis-dependent renal failure required lumbar laminectomy. During the first anesthesia attempt, induction with propofol and remifentanil led to pulseless electrical activity, necessitating resuscitation and surgery cancellation. A second attempt was planned using remimazolam for anesthesia induction and maintenance. With careful perioperative fluid management, remimazolam facilitated stable hemodynamics, and the procedure was completed uneventfully. CONCLUSION: This report demonstrates that remimazolam effectively stabilizes intraoperative hemodynamics and highlights its potential as a safe and viable anesthetic option for high-risk patients with severe comorbidities, including prior cardiac arrest.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。